Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Ava Clinical Trials Indicate Potential Future Use in Pregnancy Detection

Posted on: 01 Nov 17
Ava Clinical Trials Indicate Potential Future Use in Pregnancy Detection University of Zurich research shows Ava bracelet sensors capable of capturing known pregnancy associated physiological changes

PR Newswire

SAN FRANCISCO and ZURICH, Nov. 1, 2017

SAN FRANCISCO and ZURICH, Nov. 1, 2017 /PRNewswire/ -- Ava, best known as the maker of its popular cycle-tracking Ava bracelet, today announced that results from a recent clinical study indicates that the device's sensor technology has potential for future use in pregnancy detection.

In a recent clinical trial Ava conducted in collaboration with University Hospital of Zurich, the Ava bracelet captured physiological changes known to occur in early pregnancy. More specifically, significant differences in heart rate variability, pulse rate, and temperature between the late luteal phase in conceptive and non-conceptive cycles. Based on these findings (as published in Fertility & Sterility September 2017), researchers concluded that Ava could potentially be able to show the users in the future an indicator of pregnancy based on the changes of the physiological parameters reported at the late luteal phase. These findings are today presented in ASRM 2017, at San Antonio, Texas.

"Our findings could pave the way for the continuous assessment of the occurrence of pregnancy without any effort from the user and consequently add an innovative option for early pregnancy detection," noted Ava Co-Founder and Vice President of Research & Development Peter Stein.

Launched to the public in July 2016, Ava's cycle tracking bracelet has proven a popular option for women hoping to optimize their chances of conception by more precisely determining the fertile window. To date, the bracelet has already helped over 1,000 women conceive and Ava users from across the US and Europe are reporting about 15 pregnancies a day. This new development opens the door to a broader opportunity for the bracelet's technology to span a wider variety of women's health and wellness applications.

"We're excited about this research because it fits in with our long-term vision, which has always been for Ava to become lasting companion for women, giving them data-driven and scientifically proven insights along all stages of their reproductive lives," explained Ava Co-Founder Lea von Bidder. "This is another step in that direction."

About Ava

Founded in Switzerland in 2014 by Pascal Koenig, Philipp Tholen, Peter Stein and Lea von Bidder, Ava is a medical technology company dedicated to bringing innovation to women's reproductive health. The Ava bracelet, which received The Bump's "Best of Baby Tech CES 2017" award for fertility and pregnancy, is the company's first consumer product. It uses sensor technology combined with clinically tested data science to precisely detect a woman's entire fertile window in real time. The company is also conducting clinical studies to adapt and expand its algorithms for use in pregnancy monitoring, and future use as a non-hormonal contraceptive device. Backed by $12.3M in seed and Series A funding, Ava has operations in Zurich and San Francisco.

Media Contact:
Lindsay Stevens 
(213) 200-9638

View original content with multimedia:


PR Newswire

Last updated on: 01/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.